Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial by Maggiolo, Franco et al.
ORIGINAL RESEARCH
Bictegravir/Emtricitabine/Tenofovir Alafenamide
in Virologically Suppressed People with HIV Aged ‡ 65
Years: Week 48 Results of a Phase 3b, Open-Label Trial
Franco Maggiolo . Giuliano Rizzardini . Jean-Michel Molina . Federico Pulido .
Stephane De Wit . Linos Vandekerckhove . Juan Berenguer . Michelle L. D’Antoni .
Christiana Blair . Susan K. Chuck . David Piontkowsky . Hal Martin .
Richard Haubrich . Ian R. McNicholl . Joel Gallant
Received: January 12, 2021 / Accepted: February 19, 2021 / Published online: March 9, 2021
 The Author(s) 2021
ABSTRACT
Introduction: We report the 48-week results of
an ongoing study to assess the efficacy and
safety of switching older people with HIV to
bictegravir/emtricitabine/tenofovir alafenamide
(B/F/TAF).
Methods: This was a 96-week, phase 3b, open-
label, single-arm study (GS-US-380-4449; NCT0
3405935). Virologically suppressed individuals
aged C 65 years receiving elvitegravir/cobicistat/
emtricitabine/tenofovir alafenamide or a teno-
fovir disoproxil fumarate-based regimen were
switched to B/F/TAF. Primary endpoint was the
percentage of participants with HIV-1 RNA\50
copies/ml at week 24.
Results: Eighty-six participants (median age 69
[range 65–80] years; 87% male; 95% white) were
enrolled and treated in five European countries.
Rates of virologic suppression were 97.7% at
week 24 and 90.7% at week 48; none had HIV-1
RNA C 50 copies/ml, and 100% had virologic
suppression by missing = excluded analysis at
both time points. No treatment-emergent
resistance was observed. There were no grade
3–4 study drug-related adverse events (AEs) or
study drug-related serious AEs or deaths. Three
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AEs led to premature discontinuation; one
(moderate abdominal discomfort) was attrib-
uted to the study drug by the investigator. At
week 48, median changes from baseline in
weight and estimated glomerular filtration rate
were ? 0.1 kg (interquartile range [IQR] - 1.0,
2.3) and - 6.0 ml/min (IQR - 10.2, 0.0),
respectively. There were no clinically relevant
changes from baseline to week 48 in fasting
lipid parameters. Treatment satisfaction
improved, and health-related quality of life was
maintained from baseline through week 48.
Median adherence to the study drug was 98.6%
(IQR 96.0, 100).
Conclusions: Switching to B/F/TAF was effec-
tive and well tolerated through 48 weeks in
virologically suppressed adults aged C 65 years.
Trial Registration: ClinicalTrials.gov identifier,
NCT03405935.
Keywords: Age; Bictegravir; Clinical trial;
Emtricitabine; HIV; Older; Safety; Tenofovir
alafenamide
Key Summary Points
Why carry out this study?
People with HIV are living longer; older
individuals with HIV are more likely to
experience comorbidities and
polypharmacy.
Ensuring the safety and tolerability of
antiretroviral therapy in this population is
crucial.
We assessed the virologic efficacy and
safety of switching to bictegravir/
emtricitabine/tenofovir alafenamide (B/F/
TAF) in virologically suppressed people
living with HIV (PLWH) aged C 65 years.
What was learned from the study?
Rates of virologic suppression were 97.7%
at week 24 and 90.7% at week 48, and
there were no grade 3–4 study drug-related
adverse events (AEs) or study drug-related
serious AEs or deaths.
Switching to B/F/TAF was effective and
well tolerated through 48 weeks in
virologically suppressed adults aged C 65
years.
The findings represent an important
addition to the evidence base in older
PLWH.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14054402.
INTRODUCTION
Over the past 2 decades, people with HIV have
been living longer [1]. Individuals
aged C 65 years comprised 16% of the HIV-
positive population in the USA in 2015 [2], and
globally the number of people living with HIV
(PLWH) aged C 50 years exceeded 4.2 million
in 2013, with the highest burden reported in
sub-Saharan Africa (2.5 million) followed by
Western/Central Europe and North America
(* 800,000) and the Asia-Pacific region
(* 400,000) [3]. A recent analysis of the Swiss
HIV Cohort found that PLWH aged C 65 years
took more additional medications and more
complex antiretroviral therapy (ART) regimens
than younger PLWH [4]. A French retrospective
cohort study of[9000 PLWH aged C 65 years
receiving combined ART found that drug–drug
interactions (DDIs) were frequent (17% of
individuals experienced C 1 DDI), which sub-
stantially increased healthcare costs relative to
propensity score-matched PLWH without DDIs
[5]. As older individuals are at increased risk of
comorbidities and may experience challenges
with polypharmacy, ensuring the safety and
tolerability of ART in this population is crucial
[6].
First-line ART usually consists of two nucle-
oside reverse transcriptase inhibitors (NRTIs)
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plus an integrase strand transfer inhibitor
(INSTI) [7–9]. Guidelines recognize that a treat-
ment switch may be considered in virologically
suppressed PLWH to improve safety or tolera-
bility, for regimen simplification, or to avoid
DDIs [8, 9].
Bictegravir (BIC, B) is a potent INSTI and has
a high barrier to resistance and in vitro activity
against most INSTI-resistant variants [10]. Its
pharmacokinetic properties enable once-daily
dosing without a boosting agent [11]. Tenofovir
alafenamide (TAF) is a prodrug of tenofovir that
is associated with 90% lower plasma tenofovir
levels than tenofovir disoproxil fumarate (TDF),
reducing renal and bone toxicity [12]. BIC has
been co-formulated with the guideline-recom-
mended NRTI backbone, emtricitabine (FTC, F)
and TAF for once-daily, single-tablet treatment
of HIV-1 infection [13]. The combination is
associated with low potential for DDIs [14]. The
efficacy and safety of B/F/TAF have been
demonstrated in both treatment-naı̈ve and
virologically suppressed PLWH switching from
another treatment regimen [13, 15–18].
Although these trials were carried out in adult
participants (C 18 years) with no other entry
restriction based on age, clinical trial entry cri-
teria (e.g., restricting comorbidities) increase
the likelihood that older PLWH may be exclu-
ded from trials. Thus, older PLWH are generally
underrepresented in ART trials [19].
Here we report the 48-week results of an
ongoing study to assess the virologic efficacy
and safety of switching to B/F/TAF in virologi-
cally suppressed PLWH aged C 65 years.
METHODS
Study Design and Participants
This ongoing phase 3b, multicenter, open-label,
single-arm study (GS-US-380-4449; NCT03405
935) is being conducted in Belgium, France,
Italy, Spain, and the UK. The study was
approved by the institutional review boards or
independent ethics committees at each partici-
pating site and was performed in accordance
with Good Clinical Practice and the Declaration
of Helsinki. Study-related procedures were
conducted with the understanding and
informed consent of each participant.
Key inclusion criteria were age C 65 years,
treatment with elvitegravir/cobicistat/emtric-
itabine/tenofovir alafenamide (E/C/F/TAF) or
F/TDF plus a third agent (if they were partici-
pating in or had participated in study GS-US-
292-1826 [NCT02616783; a study examining a
switch from TDF to E/C/F/TAF in PLWH
aged C 60 years]) for C 3 months, plasma HIV-1
RNA\50 copies/ml before and at screening
(transient detectable viremia C 50 and\400
copies/ml before screening was acceptable) and
an estimated glomerular filtration rate calcu-
lated using the Cockcroft-Gault equation
(eGFRCG) C 30 ml/min. Principal exclusion cri-
teria were opportunistic illness indicative of
stage 3 HIV infection, resistance to any of the
three components of B/F/TAF, clinically signif-
icant electrocardiogram abnormalities, decom-
pensated cirrhosis and serious infections other
than HIV-1 (e.g., acute hepatitis/active
tuberculosis).
Study participants switched from their pre-
ceding therapy to receive oral B/F/TAF (50/200/
25 mg) once daily for 96 weeks. Clinic visits
were scheduled at baseline (day 1) and at the
end of weeks 4, 12, 24, 36 and 48.
Outcomes and Assessments
The primary endpoint was the percentage of
participants with HIV RNA\50 copies/ml at
week 24 as defined by the US Food and Drug
Administration Snapshot algorithm (Snapshot)
[20]. Secondary endpoints included the pro-
portion of participants with HIV RNA\50
copies/ml at week 48 (Snapshot) and the safety
and tolerability of B/F/TAF, as assessed by
adverse events (AEs), through week 48. Other
pre-specified endpoints were: the proportion of
participants with HIV RNA\50 copies/ml at
weeks 24 and 48, whereby missing data were
treated as treatment failures (‘‘missing = fail-
ure’’); the proportion of participants with HIV
RNA\50 copies/ml at weeks 24 and 48,
whereby missing data were excluded (‘‘miss-
ing = excluded’’); the change from baseline in
CD4? cell count and percentage at weeks 24
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and 48. The percentages of participants with
HIV RNA\20 copies/ml (Snapshot) were eval-
uated as a supportive endpoint. Additional
assessments included: patient satisfaction after
switching to B/F/TAF, as assessed by HIV Treat-
ment Satisfaction Questionnaire Status
(HIVTSQs) and HIV Treatment Satisfaction
Questionnaire Change (HIVTSQc); health-re-
lated quality of life through week 48, as assessed
by EuroQol 5 Dimensions (EQ-5D) patient
questionnaire (visual analog scale [VAS] and
index score), Short Form 36 Health Survey (SF-
36) and Functional Assessment of Chronic Ill-
ness Therapy-Fatigue (FACIT-F); and adherence
to study treatment through week 48, calculated
based on pill counts for participants who
returned C 1 bottle and using the VAS adher-
ence questionnaire.
Plasma HIV-1 RNA, CD4? cell count,
patient-reported outcomes (PROs), adherence,
AEs (coded using the Medical Dictionary for
Regulatory Activities), eGFRCG, standard labo-
ratory parameters and vital signs were assessed
at each clinic visit. Safety data were collected for
30 days after the last dose of study drug for
participants who permanently discontinued the
study drug.
The presence of pre-existing resistance-asso-
ciated mutations (RAMs) in protease (PR),
reverse transcriptase (RT) and integrase (IN)
genes was evaluated by historical genotypes, if
available, and by HIV-1 proviral DNA genotype
testing (GenoSure Archive, Monogram Bio-
sciences, San Francisco, CA, USA), which was
performed retrospectively using baseline sam-
ples. The GenoSure Archive assay utilizes next-
generation sequencing (NGS) technology but
generates a consensus sequence from the NGS
data and reports a population-like genotype
(the report cut-off is unknown). APOBEC3G-
induced hypermutations were removed by
bioinformatics filters.
Resistance analysis for emergent mutations
was performed in participants with virologic
failure (defined as a rebound in HIV-1 RNA C 50
copies/ml that was subsequently confirmed
and C 200 copies/ml at the next scheduled/
unscheduled visit or as HIV-1 RNA C 200
copies/ml at study drug discontinuation or
week 48). Testing included the genotype and
phenotype of HIV PR, RT and IN genes (Phe-
noSense GT, GeneSeq IN, and PhenoSense
IN; Monogram Biosciences) at the time point
when virologic failure was confirmed.
Statistical Analysis
Sample size was based on the feasibility of
conducting a study in individuals
aged C 65 years. Efficacy analyses were based on
the full analysis set, which comprised all
enrolled participants who received C 1 dose of
study drug and did not have any major protocol
violations (defined as ART regimen at study
entry other than E/C/F/TAF fixed-dose combi-
nation [or FTC/TDF ? third agent if currently or
previously participated in study GS-US-292-
1826] and ART regimen at study entry
for\ 3 months). The safety analysis set inclu-
ded all enrolled participants who received C 1
dose of study drug.
Statistical analyses were performed using
SAS version 9.4 (SAS Institute Inc., Cary, NC,
USA). The Clopper-Pearson exact method was
used to calculate 95% confidence intervals (CIs)
for the proportion of participants with HIV-1
RNA\50 copies/ml. Descriptive statistics were
used to summarize changes from baseline in
CD4? cell count, percentage of CD4? cells at
each visit, AEs and clinical laboratory data.
Changes from baseline in fasting lipids and
glucose were tested using the two-sided Wil-
coxon signed-rank test.
RESULTS
A total of 90 participants were screened, of
whom 86 were enrolled and treated (see Fig. S1
in the electronic supplementary material).
Three participants discontinued treatment early
(before week 48) because of AEs, two of which
were considered unrelated to the study drug.
Table 1 shows the baseline demographics for
the treated participants (safety analysis set). The
median age of participants was 69 (range 65–80)
years. Most participants were male (87%) and
white (95%), and the median body mass index
was 26.6 (range 17.5–35.9) kg/m2. Most (92%)
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Table 1 Participants’ baseline demographics and disease characteristics (safety analysis set, N = 86)
Parameter Value
Median age, years (range) 69 (65–80)




Not permitted to be disclosed 3 (3.5)
Hispanic/Latino ethnicity, n (%) 12 (14.5)
Median weight, kg (range) 78.3 (49.0–110.0)
Median body mass index, kg/m2 (range) 26.6 (17.5–35.9)
Median eGFRCG, ml/min (range) 76.2 (39.6–130.2)
HIV RNA\ 50 copies/ml, n (%) 84 (97.7)
HIV RNA\ 20 copies/ml, n (%) 80 (93.0)
CD4?
Median CD4? count, cells/mm3 (range) 676 (132–1385)
Median CD4? percentage (range) 35.3 (11.1–59.6)
Renal markers
Median RBP:Cr, lg/g (IQR) 139.3 (92.3–218.5)
Median b-2 m:Cr lg/g (IQR) 72.0 (26.8–194.6)
Lipids
Median total fasting lipids, mg/dl (IQR) 191 (167–227)
Median low-density lipoprotein, mg/dl (IQR) 117 (95–140)
Median high-density lipoprotein, mg/dl (IQR) 51 (44–58)
Median triglycerides, mg/dl (IQR) 131 (99–173)
Total cholesterol:high-density lipoprotein 3.9 (3.3–4.5)
Glucose, mg/dl (IQR) 102 (91–119)





NVP ? F/TDF 1 (1.2)
Chronica non-ARV medications, median (IQR) 3.0 (2–5)
Chronica non-ARV medications by system organ class, n (%)
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were receiving E/C/F/TAF before switching to
B/F/TAF.
In the primary efficacy analysis, the rate of
virologic suppression (HIV-1 RNA\50 copies/
ml) was 97.7% (95% CI 91.9–99.7) at week 24
and 90.7% (95% CI 82.5–95.9) at week 48
(Fig. 1). The difference was mainly
attributable to virologic data being unavailable
in more participants at week 48 than week 24,
including for one participant who discontinued
treatment between weeks 24 and 48 (see Fig. S1
in the electronic supplementary material). No
participants had HIV-1 RNA C 50 copies/ml at
either time point (Fig. 1). Results of the
missing = failure and missing = excluded anal-
yses were consistent with the primary analysis.
When missing data were treated as failures, the
rate of virologic suppression remained at 97.7%
at week 24 and 90.7% at week 48. When missing
data were excluded, the rate of virologic sup-
pression was 100.0% at weeks 24 and 48.
The percentages of participants with HIV-1
RNA\20 copies/ml were 94.2% (95% CI
87.0–98.1) and 88.4% (95% CI 79.7–94.3) at
weeks 24 and 48, respectively. Both the number
and percentage of CD4? cells were maintained
during 48 weeks’ treatment with B/F/TAF (see
Table S1 in the electronic supplementary
material). None of the 86 participants who
received the study drug exhibited virologic
failure, and no treatment-emergent resistance
occurred through week 48.
Baseline proviral DNA and/or historical
genotype results were available for 84/86
(97.7%) participants for the PR/RT genes and
83/86 (96.5%) for the IN gene. Pre-existing
RAMs were observed in the study population
(see Table S2 in the electronic supplementary
material). In total, five participants had proto-
col-defined exclusionary mutations in their
proviral DNA genotypes that were captured
retrospectively using the baseline visit sample.
Primary NRTI-associated resistance mutations
were observed in nine (10.7%) participants: of
these, two had C 3 thymidine analog mutations
Table 1 continued
Parameter Value
Cardiovascular system 55 (64.0)
Gastrointestinal tract 54 (62.8)
Nervous system 38 (44.2)
Blood and blood-forming organs 23 (26.7)
Musculoskeletal system 20 (23.3)
Genitourinary system and sex hormones 18 (20.9)
ARV antiretroviral, b-2 m:Cr beta-2-microglobulin to creatinine ratio, C cobicistat, E elvitegravir, EFV efavirenz, eGFRCG
estimated glomerular filtration rate calculated with the Cockcroft-Gault equation, F emtricitabine, IQR interquartile range,
NVP nevirapine, RBP:Cr retinol-binding protein to creatinine ratio, RPV rilpivirine, TAF tenofovir alafenamide, TDF
tenofovir disoproxil fumarate
a Oral or inhaled medications taken for C 30 days
Fig. 1 Virologic outcomes at weeks 24 and 48 (primary
efficacy endpoint: proportion of participants with HIV
RNA\ 50 copies/ml at week 24) (full analysis set,
N = 86). Annotated numbers show the number of
patients
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(TAMs) and three had M184V (two of whom
also had C 3 TAMs that included M41L). Pri-
mary non-nucleoside reverse transcriptase
inhibitor (NNRTI)-associated resistance
mutations were observed in 10 (11.9%) partici-
pants. Primary IN mutations were observed in
one (1.2%) participant. All participants with
exclusionary mutations maintained HIV-1
RNA\50 copies/ml through week 48.
AEs were reported in 70/86 participants
(81.4%) (Table 2). Serious AEs (SAEs) were
reported in seven participants (8.1%); all were
considered unrelated to study medication. AEs
that led to study drug discontinuation were
abdominal discomfort (moderate, attributed to
study drug by the investigator), alcohol with-
drawal and benzodiazepine withdrawal (n = 1
for each; not considered related to study drug).
No deaths were reported. There were no grade
3–4 study drug-related AEs.
The most common AEs (C 3% of partici-
pants) were bronchitis, arthralgia, hypertension
and nasopharyngitis (Table 2). AEs attributed to
treatment by the investigator occurred in nine
participants (10.5%): abdominal discomfort,
abnormal feces, constipation, dizziness,
gamma-glutamyl transferase increased, insom-
nia, myalgia, pruritus and weight increase
(n = 1 [1.2%] for each). The median change in
weight at week 48 was ? 0.1 kg (interquartile
range [IQR] - 1.0, 2.3). In seven participants
who switched from a TDF-based regimen to B/F/
TAF, four had a weight increase (? 3
to ? 4.5 kg) and three had a weight decrease
(- 2.5 to - 3 kg).
As anticipated based on the known effects of
BIC, eGFRCG decreased by week 4 but changed
little thereafter (Fig. 2a). The median change
from baseline in eGFRCG at week 48
was - 6.0 ml/min (IQR - 10.2, 0.0). No partic-
ipants developed proximal tubulopathy,
including Fanconi syndrome. Retinol-binding
protein/creatinine decreased by a median of
15.1%, and b-2-microglobulin/creatinine
increased by a median of 31.6% at week 48 (see
Fig. S2 in the electronic supplementary mate-
rial). There were no hepatic SAEs, and no hep-
atic, bone or renal AEs resulted in
discontinuation of the study drug.
Median total cholesterol, low-density
lipoprotein, high-density lipoprotein (HDL),
total cholesterol:HDL ratio and triglyceride
levels all declined from baseline to week 48, but
only total cholesterol and triglyceride changes
Table 2 Summary of treatment-emergent adverse events
(safety analysis set, N = 86)
Summary of adverse events Incidence,
n (%)
Any adverse event 70 (81.4)
Grade 3–4 adverse event 7 (8.1)
Any drug-related adverse event 9 (10.5)
Grade 3–4 drug-related adverse event 0
Any serious adverse event 7 (8.1)
Drug-related serious adverse event 0
Adverse event leading to premature
discontinuation of study drug
3 (3.5)a













Upper respiratory tract infection 3 (3.5)
Visual impairment 3 (3.5)
a One participant had an adverse event of abdominal
discomfort (grade 2), considered related to study drug; one
had a serious adverse event of alcohol withdrawal (grade 3),
considered not related to study drug; one had an adverse
event of benzodiazepine withdrawal (grade 2), considered
not related to study drug
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Fig. 2 Change from baseline in a the estimated glomerular
filtration rate calculated with Cockcroft-Gault equation
(eGFRCG) and b fasting lipids and glucose at week 48
(safety analysis set). Error bars in part a represent
interquartile range. Error bars in part b represent Q1 to
Q3. P values calculated using the two-sided Wilcoxon
signed-rank test. HDL high-density lipoprotein, LDL low-
density lipoprotein, Q quartile
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were statistically significant (Fig. 2b). Median
plasma glucose increased by 1.0 mg/dl at week
48 (not statistically significant; Fig. 2b). Median
values for hematology and clinical chemistry
parameters were generally within reference
ranges (data not shown).
An overall treatment satisfaction score was
calculated as the sum of the responses to the
questions in the HIVTSQ. At baseline, treatment
satisfaction was high with a median total score
of 58.0 (IQR 51.0, 60.0) (scored from 0 to 60;
unfavorable to favorable). At week 48, treat-
ment satisfaction improved as indicated by a
median total score of 28.0 (IQR 14.0, 30.0) on
the post-baseline change form (scored from
- 30 to 30; unfavorable to favorable).
The median EQ-VAS score (scale 0 to 100,
representing worst imaginable to best imagin-
able self-rated health, respectively) was 85 (IQR
75, 95) at baseline and 88 (IQR 80, 95) at
week 48. Similarly, the EQ-5D index score
responses (scale - 0.594 to 1.000; worst to best
health status) indicated that ‘‘no problems’’
were reported in most participants’ health sta-
tus at baseline (median score 1.000 [IQR 0.796,
1.000]) and at week 48 (median change from
baseline 0 [IQR –0.140, 0]). Scores for each of
the EQ-5D dimensions remained consistent
from baseline through week 48. There was no
change in overall health at week 48 versus
baseline in 53.2% of participants, worsened
health in 29.1% and improved health in 17.7%.
Week 48 scores for subdomains of the SF-36 and
FACIT-F were consistent with those reported at
baseline (data not shown).
Eighty-five of 86 participants returned C 1
bottle and had calculable adherence. As of week
48, the median adherence to study drug was
98.6% (IQR 96.0, 100), and most participants
(77.6%) had adherence of C 95% up to the
week 48 visit. For 19 participants who had
\95% adherence, 14 (73.7%) had a week 48
Snapshot result of HIV-1 RNA\ 50 copies/ml
and three (15.8%) discontinued the study (be-
cause of AE/death), but the last available HIV-1
RNA measurement was\50 copies/ml, and two
(10.5%) had missing data. Three participants
(3.5%) had adherence\ 80% up to week 48,
with the minimum adherence 52.1%. Each of
these three participants had a week 48 Snapshot
result of HIV-1 RNA\ 50 copies/ml. Median
self-reported adherence based on the VAS
adherence questionnaire was 100% for all post-
baseline visits through week 48.
DISCUSSION
In the present study of B/F/TAF for the treat-
ment of virologically suppressed PLWH
aged C 65 years, we observed high rates of viral
suppression, no HIV-1 RNA values[ 50 copies/
ml and no treatment-emergent resistance. B/F/
TAF was well tolerated, with no drug-related
grade 3–4 AEs/SAEs and no discontinuations
due to renal, hepatic or bone-related AEs. Posi-
tive PROs—including measures of health-re-
lated quality of life, patient satisfaction and
treatment adherence—reflected the efficacy and
safety results.
The rates of virologic suppression (HIV-1
RNA\50 copies/ml) observed in PLWH
aged C 65 years in the present study (week 24,
98%; week 48, 91%) are consistent with previ-
ously reported rates in younger adults who
switched to B/F/TAF [9, 13, 15], suggesting no
difference in virologic response between older
and younger patients. For example, Molina and
colleagues reported that switching to B/F/TAF
was non-inferior to remaining on dolutegravir/
abacavir/lamivudine in virologically suppressed
adults, with 94% of participants in the B/F/TAF
group (median age 47 years) achieving virologic
suppression at week 48 [16]. Similarly, Daar and
colleagues reported that switching to B/F/TAF
was non-inferior to continuing boosted pro-
tease inhibitor (PI)-based therapy in virologi-
cally suppressed adults, with 92% of
participants who switched to B/F/TAF (median
age 48 years) achieving virologic suppression at
week 48 [13]. Finally, Kityo and colleagues
reported that switching to B/F/TAF was non-
inferior to remaining on a baseline regimen in
virologically suppressed women, with 96% of
women in the B/F/TAF group (median age
39 years) achieving virologic suppression at
week 48 [15].
The similarity in virologic responses with
B/F/TAF between older and younger patients
has also been noted with other ART regimens
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[21–24]. For example, in a pooled analysis of 19
prospective cohort studies in the North Ameri-
can AIDS Cohort Collaboration on Research
and Design (NA-ACCORD), cumulative rates of
HIV RNA B 500 copies/ml in the first 2 years
after ART initiation (NNRTI-based/boosted PI-
based regimens) did not differ by age [21].
Additionally, a cross-sectional analysis of the
French Dat’AIDS cohort reported that plasma
HIV RNA was\ 50 copies/ml in 90.6% and
90.9% of individuals receiving ART who were
aged 50–74 years and C 75 years, respectively
[24].
Notably, 100% of individuals in the present
study with pre-existing archived NRTI resis-
tance by proviral DNA genotype (n = 9; none
with K65R) achieved successful virologic out-
comes with no emergent resistance. This is
consistent with recent analyses of the efficacy of
switching to B/F/TAF in studies GS-US-380-
1878, GS-US-380-1844, GS-US-380-4030 and
GS-US-380-4580 in PLWH with pre-existing
resistance [25–28]. High rates of virologic sup-
pression were observed in the overall popula-
tion and in individuals with pre-existing
resistance, indicating that B/F/TAF is an effec-
tive treatment option for virologically sup-
pressed patients with archived NRTI resistance
[25]. In addition, no emergent resistance has
been observed in clinical trials of B/F/TAF to
date [13, 15–18, 25, 28–30].
The safety profile, including overall inci-
dence and types of drug-related AEs, was con-
sistent with that expected with B/F/TAF based
on previous studies [9, 13, 15, 31]. There were
no indicators of bone- or kidney-related toxic-
ity, which are of special concern in older
patients, who experience loss of glomerular
function and bone mineral density as they age.
No participants developed proximal tubulopa-
thy, and changes in renal biomarkers were
consistent with the known renal safety profile
of TAF. The observed decline in eGFRCG is
consistent with the known effect of BIC as an
inhibitor of the renal transporters, organic
cation transporter 2 (OCT2) and multidrug and
toxin extrusion 1 (MATE1; noting the effect is
on the estimated measurement of GFR and not
the actual GFR). However, as most participants
had been receiving E/C/F/TAF before switching
to B/F/TAF, and cobicistat is also an inhibitor of
cation transporters, predominantly MATE1
[32, 33], it is difficult to draw direct conclusions
on the effect of BIC on renal transporters in this
older patient population.
The lack of weight gain is an interesting
finding, as INSTI treatment has been associated
with weight gain [34, 35]. The lack of additional
weight gain following the switch to B/F/TAF is
reassuring given that most participants were on
an elvitegravir-containing therapy at baseline,
and elvitegravir appears to be associated with
the least amount of weight gain among the
INSTIs [35]. However, most patients in this
study were taking TAF. Unlike TDF, which has
been associated with weight loss or suppression
of expected weight gain, there is no weight-
suppressive effect of TAF [34]. Thus, patients
switching from TDF might be expected to gain
weight after a switch to B/F/TAF; however, we
did not see any trend in the small number of
patients studied. Furthermore, the lack of
observed weight gain should also be considered
in the context of the predominantly white male
study population; weight gain with INSTI ther-
apy has been reported to be greater in female
and black PLWH [34, 35].
Patient-reported treatment satisfaction was
higher at week 48 with B/F/TAF versus the pre-
switch baseline regimens. While this is an
encouraging result, without a true control
group, it is difficult to reach firm conclusions
around treatment satisfaction. Although not
directly assessed, potential explanations for the
suggested greater treatment satisfaction with
B/F/TAF could include the small pill size, fewer
DDIs or reduced gastrointestinal side effects.
The use of unboosted INSTIs as third agents has
been shown to be associated with a lower risk of
experiencing ‘‘red-flag’’ and ‘‘orange-flag’’ DDIs
[36]. On this basis, it was proposed that
unboosted INSTI-based regimens should be
considered for patients at a high risk of experi-
encing harm from DDIs, e.g., those with organ
dysfunction, comorbidities and polypharmacy
[36]. However, we did not measure the occur-
rence of DDIs when switching regimens in this
study. The present findings suggest that B/F/TAF
is an appropriate ART regimen for virologically
784 Infect Dis Ther (2021) 10:775–788
suppressed PLWH aged C 65 years who wish to
switch.
A strength of the study is that it specifically
and prospectively investigated the effects of
B/F/TAF in PLWH aged C 65 years, a patient
group underrepresented in ART trials. Addi-
tionally, the study design included a breadth of
outcome measures, including PROs as well as
conventional efficacy and safety assessments.
Limitations of the study include the open-
label, uncontrolled design, which increases the
risk of bias, particularly for subjective measures
such as the PROs. A formal sample size calcu-
lation was not performed, as recruitment was
based on the feasibility of enrolling elderly
patients within a reasonable time scale. Finally,
participants were mainly white men, which
may be representative of the current older
population of PLWH in many resource-rich
regions [37], but does not necessarily reflect
changing demographics or the characteristics of
older populations in other regions. Addition-
ally, most participants had been previously
taking E/C/F/TAF, so observed changes from
baseline in outcome measures might not be
applicable to patients switching from other
regimens. Thus, the generalizability of the
findings to clinical practice should be consid-
ered in the context of the population studied.
Nevertheless, the present findings represent an
important addition to the evidence base, as over
half of participants were [ 69 years of age,
meaning that the study cohort was truly an
elderly population, in contrast to other studies
in ‘‘elderly’’ patients that have often included
much younger patients (e.g., aged[ 50 years).
CONCLUSION
Switching to B/F/TAF was effective and well
tolerated in virologically suppressed adults
aged C 65 years through 48 weeks. Treatment
satisfaction was higher with B/F/TAF than with
baseline treatment, although there were no
changes in other PROs in response to the
switch. The study is ongoing and will continue
through 96 weeks, providing additional data on
the long-term efficacy, safety and tolerability of
B/F/TAF in this age group.
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